

Cinqair (reslizumab) Fasenra (benralizumab) Nucala (mepolizumab)

| Override(s) | Approval Duration |
|---------------------|-------------------------------|
| Prior Authorization | Initial requests: 6 months |
| Quantity Limit | Continuation requests: 1 year |

| Medications | Quantity Limit | Dosing Limit |
|--|--|-----------------------|
| Cinqair (reslizumab) 100 mg vial | | 3 mg/kg every 4 weeks |
| Fasenra (benralizumab) 10 mg/0.5 mL prefilled syringe | 10 mg (1 syringe) every 8 weeks | |
| Fasenra (benralizumab) 30 mg/mL prefilled syringe/autoinjector | 30 mg (1 syringe/autoinjector) every 8 weeks | |
| Nucala (mepolizumab) 40 mg/0.4 mL prefilled syringe | 40 mg (1 syringe) every 4 weeks | |
| Nucala (mepolizumab) 100 mg vial, 100 mg/mL prefilled syringe/autoinjector | 100 mg (1 vial/syringe/autoinjector) every 4 weeks | |

For Fasenra, may approve 1 additional 30 mg/mL prefilled syringe/autoinjector or 10 mg/mL prefilled syringe at week 4 if using for severe eosinophilic asthma. The total allowed quantity for initiation of therapy is 30 mg once every 4 weeks for the first 3 doses for individuals age 12 and older or age 6 – 11 weighing greater than or equal to 35 kg. The total allowed quantity for initiation of therapy is 10 mg once every 4 weeks for the first 3 doses for individuals age 6 – 11 weighing less than 35 kg.

For Fasenra, may approve 30 mg/mL prefilled syringe/autoinjector every 4 weeks if individual is using for eosinophilic granulomatosis with polyangiitis (EGPA).

For Nucala 100 mg vial/prefilled syringe/autoinjector, may approve up to 300 mg (3 vials/syringes/autoinjectors) every 4 weeks if individual is using for eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES).

APPROVAL CRITERIA

Initial requests for Cinqair (reslizumab) may be approved for severe **eosinophilic asthma** when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**

- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 mL after albuterol administration;

AND

- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long-acting muscarinic antagonists or oral corticosteroids) (GINA 2025); **AND**
- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual’s usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013); **AND**
- VI. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 400 cells/microliter (400 cells/mm³) at initiation of therapy.

Initial requests for Fasenra (benralizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Individual is 6 years of age or older; **AND**
- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**
- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 milliliters (mL) after albuterol administration;

AND

- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long acting muscarinic antagonists or oral corticosteroids) (GINA 2025);

AND

- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual’s usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013);

AND

- VI. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter (150 cells/mm³) at initiation of therapy.

Initial requests for Nucala (mepolizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Individual is 6 years of age or older; **AND**
- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**
- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 milliliters (mL) after albuterol administration;

AND

- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long-acting muscarinic antagonists or oral corticosteroids) (GINA 2025); **AND**
- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual's usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013); **AND**
- VI. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter (150 cells/mm³) at initiation of therapy.

Continuation requests for Cinqair (reslizumab), Fasentra (benralizumab), or Nucala (mepolizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Treatment with Cinqair (reslizumab), Fasentra (benralizumab), or Nucala (mepolizumab) has resulted in clinical improvement in one or more of the following:
 - A. Decreased utilization of reliever medication; **OR**
 - B. Decreased frequency of exacerbations (defined as worsening of asthma that requires an increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
 - C. Increase in percent predicted FEV₁ from pretreatment baseline; **OR**
 - D. Reduction in reported asthma-related symptoms, including asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing;

AND

- II. Individual continues to use Cinqair (reslizumab), Fasentra (benralizumab), or Nucala (mepolizumab) in combination with inhaled corticosteroid-based controller therapy.

Initial requests for Fasentra (benralizumab) for **eosinophilic granulomatosis with polyangiitis** may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**

- II. Individual has a diagnosis of relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) defined as (Wechsler 2024):
 - A. A history or presence of asthma; **AND**
 - B. A blood eosinophil level of greater than 10% of leukocytes or an absolute eosinophil count of greater than 1000 cells per microliter (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease and known or suspected parasitic infection), and documentation is provided; **AND**
 - C. The presence of two or more features of eosinophilic granulomatosis with polyangiitis (including, a biopsy showing histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatosis inflammation; neuropathy, mono or poly [motor deficit or nerve conduction abnormality]; pulmonary infiltrates, non-fixed; sinonasal abnormality; cardiomyopathy; glomerulonephritis; alveolar hemorrhage; palpable purpura; antineutrophil cytoplasmic antibody [ANCA] positive status; MPO or PR3 antibody positive status); **AND**
- III. Individual is using in combination with oral corticosteroid therapy (Wechsler 2024).

Initial requests for Nucala (mepolizumab) for **eosinophilic granulomatosis with polyangiitis** when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has been diagnosed with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) defined as (Wechsler, 2017):
 - A. A history or presence of asthma; **AND**
 - B. A blood eosinophil level of greater than 10% of leukocytes or an absolute eosinophil count of greater than 1000 cells per microliter (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection), and documentation is provided; **AND**
 - C. The presence of two or more features of eosinophilic granulomatosis with polyangiitis (including, a biopsy showing histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatosis inflammation; neuropathy, mono or poly [motor deficit or nerve conduction abnormality]; pulmonary infiltrates, non-fixed; sinonasal abnormality; cardiomyopathy; glomerulonephritis; alveolar hemorrhage; palpable purpura, or antineutrophil cytoplasmic antibody [ANCA] positive status; MPO or PR3 antibody positive status); **AND**
- III. Individual is using in combination with oral corticosteroid therapy (Wechsler, 2017).

Continuation requests for Fasenra (benralizumab) or Nucala (mepolizumab) for **eosinophilic granulomatosis with polyangiitis** may be approved if the following criteria are met:

- I. Treatment with Fasenra or Nucala has resulted in clinically significant improvement in clinical signs and symptoms of disease (including but not limited to achievement of remission, decreased frequency of relapses, reduction in corticosteroid dosage).

Initial requests for Nucala (mepolizumab) for **hypereosinophilic syndrome (HES)** may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has been diagnosed with hypereosinophilic syndrome (HES) for at least six months; **AND**
- III. Individual has had a trial and inadequate response to oral corticosteroids (WHO 2022); **AND**
- IV. Documentation is provided that individual has experienced two or more HES flares within the past 12 months requiring escalation in therapy (increase in oral corticosteroid dose or increase/addition of immunosuppressive or cytotoxic therapy); **AND**
- V. Documentation is provided that individual has a blood eosinophil count greater than or equal to 1,000 cells/microliter.

Continuation requests for Nucala (mepolizumab) for **hypereosinophilic syndrome (HES)** may be approved if the following criteria are met:

- I. Treatment with Nucala has resulted in confirmed clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decrease or absence of HES flares, improvement in fatigue).

Nucala (mepolizumab) for **hypereosinophilic syndrome (HES)** may not be approved for the following:

- I. Individuals with non-hematologic secondary HES (including but not limited to drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy); **OR**
- II. Individuals with FIP1L1-PDGFR α kinase-positive HES.

Initial requests for Nucala (mepolizumab) for **chronic rhinosinusitis with nasal polyps (CRSwNP)** may be if approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP); **AND**
- III. Documentation is provided that there is presence of nasal polyps demonstrated on one of the following (AAO-HNS 2025):
 - A. Anterior rhinoscopy; **OR**
 - B. Nasal endoscopy; **OR**
 - C. Computed tomography (CT); **AND**
- IV. Individual has had a trial and inadequate response to maintenance intranasal corticosteroids; **AND**
- V. Individual is refractory to or is ineligible or intolerant to the following (AAAAI/ACAAI 2014, JTFPP 2022):

- A. Systemic corticosteroids; **OR**
- B. Sinonasal surgery; **AND**

VI. Individual is requesting Nucala as add-on therapy to maintenance intranasal corticosteroids.

Continuation requests for Nucala (mepolizumab) for **chronic rhinosinusitis with nasal polyps (CRSwNP)** may be approved if the following criteria are met:

- I. Treatment with Nucala has resulted in confirmed clinically significant improvement in clinical signs and symptoms of disease (including but not limited to improvement in nasal congestion or reduced nasal polyp size); **AND**
- II. Individual continues to use Nucala in combination with maintenance intranasal corticosteroids.

Initial requests for Nucala (mepolizumab) for **chronic obstructive pulmonary disease** may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype; **AND**
- III. COPD diagnosis is demonstrated by post-bronchodilator FEV₁/FVC <0.7; **AND**
- IV. Individual has moderate to severe airflow obstruction demonstrated by post-bronchodilator FEV₁ 20% - 80% predicted; **AND**
- V. Documentation is provided that individual is currently on long-acting muscarinic antagonist (LAMA) in combination with long-acting beta-2 agonist (LABA) and inhaled corticosteroid (ICS); **AND**
- VI. Individual meets one of the following:
 - A. Two or more moderate COPD exacerbations in the prior 12 months requiring use of a systemic corticosteroid or antibiotic; **OR**
 - B. One or more severe COPD exacerbation in the prior 12 months requiring more than 24 hours hospitalization; **AND**
- VII. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease and known or suspected parasitic infection) greater than or equal to 300 cells/microliter (300 cells/mm³).

Continuation requests for Nucala (mepolizumab) for **chronic obstructive pulmonary disease** may be approved if the following criteria are met:

- I. Treatment with Nucala (mepolizumab) has resulted in clinical improvement in one or more of the following:
 - A. Decreased utilization of reliever medication; **OR**
 - B. Decreased frequency or severity of exacerbations; **OR**
 - C. Increase in percent predicted FEV₁ from pretreatment baseline; **OR**
 - D. Reduction in reported COPD-related symptoms, including shortness of breath, cough, fatigue or sleep disturbance; **AND**

II. Individual continues to use Nucala in combination with ICS/LAMA/LABA therapy.

Cinqair (reslizumab) may not be approved for the following:

- I. In combination with Dupixent, Exdensus, Fasenra, Nucala, Tezspire or Xolair; **OR**
- II. May not be approved when the above criteria are not met and for all other indications.

Fasenra (benralizumab) may not be approved for the following:

- I. In combination with Cinqair, Dupixent, Exdensus, Nucala, Tezspire or Xolair; **OR**
- II. May not be approved when the above criteria are not met and for all other indications.

Nucala (mepolizumab) may not be approved for the following:

- I. In combination with Cinqair, Dupixent, Exdensus, Fasenra, Tezspire or Xolair; **OR**
- II. May not be approved when the above criteria are not met and for all other indications.

Key References:

1. Bradding P. Asthma: eosinophil disease, mast cell disease, or both? *Allergy Asthma Clin Immunol.* 2008; (4)2:84-90.
2. Chung KF, Wenzel SE, Brozek JL, et al. International European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J.* 2014; 43(2):343-373.
3. Chung SA, Langford CA, Maz M, et. al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Rheumatol.* 2021;73(8):1366-1383.
4. Cloutier MM, Baptist AP, Blake KV, et. al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol.* 2020 Dec;146(6):1217-1270.
5. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: February 1, 2026.
6. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2025. Available from: ginasthma.org/reports/. Accessed on: January 15, 2026.
8. Holguin F, Cardet JC, Chung KF, et. al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J.* 2020 Jan 2;55(1):1900588.
9. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. *N Engl J Med.* 2024;391(24):2337-2349.
10. Khoury P. Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA). Last updated: April 21, 2025. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: February 1, 2026.
11. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
12. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication Number 08-5846. Updated: August 5, 2008. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed: February 1, 2026.
13. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. *N Engl J Med.* 2017;377(17):1613-1629.
14. Payne SC, McKenna M, Buckley J, et al. American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNS). Clinical Practice Guideline: Adult Sinusitis Update. *Otolaryngology-Head and Neck Surgery.* 2025;173(5):S1-S56.
15. Peters AT, Spector S, Hsu J, et al. Joint Task Force on Practice Parameters (JTFFP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI) and the Joint Council of Allergy, Asthma & Immunology. Diagnosis and management of rhinosinusitis: a practice parameter update. *American College of Allergy, Asthma & Immunology.* 2014;113:347-385.
16. Rank MA, Chu DK, Bognanni A, et. al. The Joint Task Force on Practice Parameters (JTFFP) GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol.* 2022;S0091-6749(22)01484-1.

17. [Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2020; 146:1397-1405.](#)
18. Scirba FC, Criner GJ, Christenson SA, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. *N Engl J Med.* 2025;392(17):1710-1720.
19. Sharma S, Carr TF. Treatment of severe asthma in adolescents and adults. Last updated: October 20, 2025. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 15, 2026.
20. Shomali W, Gotlib J. World Health Organization (WHO)-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. *Am J Hematol.* 2022;97:129-148.
21. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med.* 2017; 376(20):1921-1932.
22. Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. *N Engl J Med.* 2024; 390(10):911-921.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.